DK3260118T3 - Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion - Google Patents
Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion Download PDFInfo
- Publication number
- DK3260118T3 DK3260118T3 DK17167125.8T DK17167125T DK3260118T3 DK 3260118 T3 DK3260118 T3 DK 3260118T3 DK 17167125 T DK17167125 T DK 17167125T DK 3260118 T3 DK3260118 T3 DK 3260118T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- compositions
- cognitive function
- improving cognitive
- improving
- Prior art date
Links
- 230000003920 cognitive function Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10584708P | 2008-10-16 | 2008-10-16 | |
US15263109P | 2009-02-13 | 2009-02-13 | |
US17553609P | 2009-05-05 | 2009-05-05 | |
EP09748527.0A EP2346500B1 (en) | 2008-10-16 | 2009-10-16 | Methods and compositions for improving cognitive function |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3260118T3 true DK3260118T3 (da) | 2021-04-19 |
Family
ID=41403972
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17167125.8T DK3260118T3 (da) | 2008-10-16 | 2009-10-16 | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
DK09748527.0T DK2346500T3 (da) | 2008-10-16 | 2009-10-16 | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09748527.0T DK2346500T3 (da) | 2008-10-16 | 2009-10-16 | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion |
Country Status (12)
Country | Link |
---|---|
US (5) | US20100099735A1 (da) |
EP (2) | EP3260118B1 (da) |
JP (3) | JP5917148B2 (da) |
CN (2) | CN102227217A (da) |
AU (1) | AU2009303834B2 (da) |
BR (1) | BRPI0920342A2 (da) |
CA (1) | CA2740610C (da) |
DK (2) | DK3260118T3 (da) |
EA (1) | EA033130B1 (da) |
ES (2) | ES2865504T3 (da) |
HK (2) | HK1245099A1 (da) |
WO (1) | WO2010044878A1 (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2865504T3 (es) | 2008-10-16 | 2021-10-15 | Univ Johns Hopkins | Procedimientos y composiciones para la mejora de la función cognitiva |
CN109662961A (zh) * | 2011-02-09 | 2019-04-23 | 约翰斯霍普金斯大学 | 用于改善认知功能的方法和组合物 |
EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA |
US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
EP2968257A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
MX384391B (es) | 2015-05-22 | 2025-03-14 | Agenebio Inc | Composiciones farmacéuticas de levetiracetam de liberación extendida. |
ES2747993T3 (es) * | 2015-05-22 | 2020-03-12 | Agenebio Inc | Composiciones farmacéuticas de liberación prolongada de levetiracetam |
MA43532A (fr) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals Inc | Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques |
US20200121644A1 (en) * | 2016-05-20 | 2020-04-23 | Institut Pasteur | Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities |
US10370561B2 (en) | 2016-06-28 | 2019-08-06 | Prc-Desoto International, Inc. | Urethane/urea-containing bis(alkenyl) ethers, prepolymers prepared using urethane/urea-containing bis(alkenyl) ethers, and uses thereof |
US11098222B2 (en) | 2018-07-03 | 2021-08-24 | Prc-Desoto International, Inc. | Sprayable polythioether coatings and sealants |
CN109892247B (zh) * | 2019-04-19 | 2023-08-18 | 桂林医学院 | 一种猫参与的检测大鼠认知功能的实验装置 |
CN112569216B (zh) * | 2019-09-30 | 2022-02-15 | 厦门大学 | 戊酸衍生物在治疗唐氏综合征中的应用 |
US20230270753A1 (en) * | 2020-07-10 | 2023-08-31 | Agenebio, Inc. | Combinations of gabaa alpha 5 agonists and sv2a inhibitors and methods of using in the treatment of cognitive impairment |
AU2023324882A1 (en) | 2022-08-19 | 2025-03-20 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1309692A (en) | 1970-02-13 | 1973-03-14 | Ucb Sa | N-substituted lactams |
GB1039113A (en) | 1964-08-06 | 1966-08-17 | Ucb Sa | New n-substituted lactams |
IT1045043B (it) * | 1975-08-13 | 1980-04-21 | Isf Spa | Derivati pirrolidinici |
IT1075280B (it) * | 1977-02-11 | 1985-04-22 | Isf Spa | Procedimento per la preparazione di derivati pirrolidinici |
BE864269A (fr) * | 1977-03-03 | 1978-06-16 | Parke Davis & Co | Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire |
EP0005689B1 (fr) * | 1978-05-08 | 1981-03-18 | U C B, S.A. | Nouveaux acides lactame-N-acétiques et leurs amides, leurs procédés de préparation et compositions thérapeutiques |
US4654370A (en) | 1979-03-12 | 1987-03-31 | Abbott Laboratories | Glyceryl valproates |
US4372960A (en) * | 1980-12-12 | 1983-02-08 | Warner-Lambert Company | Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators |
FR2515179A1 (fr) * | 1981-07-24 | 1983-04-29 | Hoffmann La Roche | Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique |
IL67623A (en) | 1983-01-05 | 1984-09-30 | Teva Pharma | 1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it |
IL72381A (en) * | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
US4558070A (en) * | 1983-10-26 | 1985-12-10 | Abbott Laboratories | Acid salts of valproic acid |
GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
GB8412358D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
US4668687A (en) * | 1984-07-23 | 1987-05-26 | Bristol-Myers Company | Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones |
US4913906B1 (en) | 1985-02-28 | 2000-06-06 | Yissum Res Dev Co | Controlled release dosage form of valproic acid |
JPS6222785A (ja) * | 1985-07-23 | 1987-01-30 | Sanwa Kagaku Kenkyusho:Kk | 新規な2−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤 |
IT1190133B (it) * | 1986-06-19 | 1988-02-10 | Chiesi Farma Spa | Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche |
DE3709230A1 (de) | 1987-03-20 | 1988-10-06 | Desitin Arzneimittel Gmbh | Neues calciumsalz der valproinsaeure |
JPS6422883A (en) * | 1987-07-17 | 1989-01-25 | Sanwa Kagaku Kenkyusho Co | 1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient |
ES2026198T3 (es) | 1987-07-22 | 1992-04-16 | Farvalsa Ag | Compuesto a base de acido valproico solido, estable a la humedad y metodo para su preparacion. |
HUT53607A (en) | 1989-01-17 | 1990-11-28 | Hoffmann La Roche | Process for production of derivatives of cyclohexan-acetamid |
FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
CA2067614C (en) * | 1991-05-02 | 2002-07-30 | Eiichi Otomo | Agent for improving dementia |
US5439930A (en) * | 1992-04-14 | 1995-08-08 | Russian-American Institute For New Drug Development | Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects |
US5440023A (en) * | 1992-09-18 | 1995-08-08 | Beckman Instruments, Inc. | Method for making valproic acid derivatives |
GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
US5468733A (en) | 1993-09-30 | 1995-11-21 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5516759A (en) | 1994-12-08 | 1996-05-14 | Tap Holdings Inc. | LHRH antagonists having lactam groups at the N-terminus |
IT1285801B1 (it) | 1996-10-10 | 1998-06-24 | Sigma Tau Ind Farmaceuti | Procedimento migliorato per la preparazione dell'acido valproico |
US6131106A (en) * | 1998-01-30 | 2000-10-10 | Sun Microsystems Inc | System and method for floating-point computation for numbers in delimited floating point representation |
US6620802B1 (en) * | 1999-11-23 | 2003-09-16 | Corcept Therapeutics, Inc. | Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist |
AR026610A1 (es) | 1999-12-01 | 2003-02-19 | Ucb Sa | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central |
GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
DE60138733D1 (de) * | 2000-12-28 | 2009-06-25 | Hamilton Pharmaceuticals Inc | Arzneimittel zur behandlung und vermeidung neurogener schmerzen |
US6610326B2 (en) * | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
AU2002245486B2 (en) * | 2001-02-23 | 2006-11-16 | Ucb Pharma, S.A. | Treatment of tics, tremors and related disorders |
EP1395560A1 (en) | 2001-05-23 | 2004-03-10 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
DE60135390D1 (de) * | 2001-08-22 | 2008-09-25 | Hamilton Pharmaceuticals Inc | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration |
US7235579B2 (en) | 2001-10-16 | 2007-06-26 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
US20040116506A1 (en) * | 2002-06-20 | 2004-06-17 | Krusz John Claude | Use of levetiracetam for treating or preventing acute headaches |
US7557137B2 (en) * | 2002-08-05 | 2009-07-07 | Bristol-Myers Squibb Company | Gamma-lactams as beta-secretase inhibitors |
JP2006516390A (ja) * | 2002-12-03 | 2006-07-06 | ユ セ ベ ソシエテ アノニム | 発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法 |
US7090985B2 (en) * | 2002-12-03 | 2006-08-15 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
ITMI20030573A1 (it) * | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
TW200508197A (en) | 2003-03-31 | 2005-03-01 | Ucb Sa | Indolone-acetamide derivatives, processes for preparing them and their uses |
CA2546970C (en) * | 2003-12-02 | 2011-04-26 | Ucb, S.A. | Imidazole derivatives, processes for preparing them and their uses |
US7618978B2 (en) | 2004-04-22 | 2009-11-17 | Eli Lilly And Company | Amides as BACE inhibitors |
DE602005003472T2 (de) | 2004-06-11 | 2008-09-25 | Ucb Pharma, S.A. | Verfahren zur herstellung von 2-oxo-1-pyrrolidinderivaten durch intramolekulare allylierung |
WO2006034196A1 (en) * | 2004-09-17 | 2006-03-30 | Lifelike Biomatic Inc. | Compositions for enhancing memory and methods therefor |
DE05815688T1 (de) * | 2005-01-27 | 2008-06-26 | Alembic Ltd. | Levetiracetam-formulierung mit verlängerter freisetzung |
US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
EP1871363A4 (en) * | 2005-03-30 | 2009-01-21 | Genpharm Inc | COMBINED STAGE PROCESS FOR PHARMACEUTICAL COMPOSITIONS |
WO2006128692A2 (en) | 2005-06-01 | 2006-12-07 | Ucb Pharma, S.A. | 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system |
EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
CA2631885A1 (en) | 2005-12-07 | 2007-06-14 | Ucb Pharma, S.A. | Xanthine derivatives, processes for preparing them and their uses |
US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
CA2651862A1 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US20080014271A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
WO2008021666A2 (en) * | 2006-08-18 | 2008-02-21 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
EP2152262A2 (en) | 2007-04-27 | 2010-02-17 | UCB Pharma, S.A. | New heterocyclic derivatives useful for the treatment of cns disorders |
WO2009038412A2 (en) | 2007-09-21 | 2009-03-26 | Lg Life Sciences, Ltd. | Beta-secretase inhibiting compounds |
US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
MX2010009222A (es) * | 2008-03-03 | 2010-09-28 | Ucb Pharma Sa | Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos. |
JP2010024156A (ja) | 2008-07-16 | 2010-02-04 | Ucb Pharma Sa | レベチラセタムを含む医薬組成物 |
MX2011001384A (es) | 2008-08-06 | 2011-09-27 | Gosforth Ct Holdings Pty Ltd | Composiciones y metodos para tratar trastornos psiquiatricos. |
ES2865504T3 (es) | 2008-10-16 | 2021-10-15 | Univ Johns Hopkins | Procedimientos y composiciones para la mejora de la función cognitiva |
US9125898B2 (en) * | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
AU2009317280B2 (en) | 2008-11-18 | 2014-03-06 | Ucb Pharma, S.A. | Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative |
EP2391351B1 (en) | 2009-01-29 | 2014-08-20 | UCB Pharma, S.A. | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
EP2393483B1 (en) | 2009-02-09 | 2017-06-28 | UCB Biopharma SPRL | Pharmaceutical compositions comprising brivaracetam |
WO2011015349A2 (en) | 2009-08-07 | 2011-02-10 | Ucb Pharma, S.A. | Methods for enhancing the cognitive function |
-
2009
- 2009-10-16 ES ES17167125T patent/ES2865504T3/es active Active
- 2009-10-16 DK DK17167125.8T patent/DK3260118T3/da active
- 2009-10-16 WO PCT/US2009/005647 patent/WO2010044878A1/en active Application Filing
- 2009-10-16 US US12/580,464 patent/US20100099735A1/en not_active Abandoned
- 2009-10-16 EA EA201170571A patent/EA033130B1/ru not_active IP Right Cessation
- 2009-10-16 CN CN2009801474233A patent/CN102227217A/zh active Pending
- 2009-10-16 CN CN201710440380.4A patent/CN107243007A/zh active Pending
- 2009-10-16 EP EP17167125.8A patent/EP3260118B1/en active Active
- 2009-10-16 AU AU2009303834A patent/AU2009303834B2/en active Active
- 2009-10-16 CA CA2740610A patent/CA2740610C/en active Active
- 2009-10-16 BR BRPI0920342-7A patent/BRPI0920342A2/pt not_active Application Discontinuation
- 2009-10-16 ES ES09748527.0T patent/ES2637497T3/es active Active
- 2009-10-16 DK DK09748527.0T patent/DK2346500T3/da active
- 2009-10-16 EP EP09748527.0A patent/EP2346500B1/en active Active
- 2009-10-16 JP JP2011532085A patent/JP5917148B2/ja active Active
-
2011
- 2011-11-02 US US13/287,531 patent/US8604075B2/en active Active
-
2014
- 2014-04-25 US US14/261,962 patent/US20150094352A1/en not_active Abandoned
- 2014-06-24 JP JP2014129145A patent/JP2014169339A/ja not_active Withdrawn
-
2016
- 2016-05-25 JP JP2016103917A patent/JP6271641B2/ja active Active
-
2018
- 2018-04-06 HK HK18104537.2A patent/HK1245099A1/zh unknown
- 2018-06-26 HK HK18108219.8A patent/HK1248543A1/zh unknown
-
2021
- 2021-08-17 US US17/404,124 patent/US20220218665A1/en not_active Abandoned
-
2023
- 2023-10-03 US US18/376,127 patent/US20240293363A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ES2865504T3 (es) | 2021-10-15 |
US8604075B2 (en) | 2013-12-10 |
EA201170571A1 (ru) | 2011-12-30 |
HK1248543A1 (zh) | 2018-10-19 |
JP2012505883A (ja) | 2012-03-08 |
AU2009303834B2 (en) | 2016-08-11 |
HK1245099A1 (zh) | 2018-08-24 |
WO2010044878A1 (en) | 2010-04-22 |
US20120046336A1 (en) | 2012-02-23 |
EP3260118B1 (en) | 2021-03-24 |
BRPI0920342A2 (pt) | 2020-06-23 |
US20240293363A1 (en) | 2024-09-05 |
JP2016147915A (ja) | 2016-08-18 |
CN102227217A (zh) | 2011-10-26 |
JP5917148B2 (ja) | 2016-05-11 |
EP3260118A1 (en) | 2017-12-27 |
JP6271641B2 (ja) | 2018-01-31 |
CA2740610A1 (en) | 2010-04-22 |
EP2346500B1 (en) | 2017-05-17 |
EP2346500A1 (en) | 2011-07-27 |
US20100099735A1 (en) | 2010-04-22 |
JP2014169339A (ja) | 2014-09-18 |
US20150094352A1 (en) | 2015-04-02 |
CN107243007A (zh) | 2017-10-13 |
EA033130B1 (ru) | 2019-08-30 |
ES2637497T3 (es) | 2017-10-13 |
US20220218665A1 (en) | 2022-07-14 |
AU2009303834A1 (en) | 2010-04-22 |
CA2740610C (en) | 2020-01-07 |
DK2346500T3 (da) | 2017-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3260118T3 (da) | Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion | |
DK2068927T3 (da) | Fremgangsmåder til reducering af eosinofilniveauer | |
DK2470656T3 (da) | Sammensætning til hæmning af genekspression og anvendelser heraf | |
DK3663411T3 (da) | Fremgangsmåder til digital pcr | |
DK2323638T3 (da) | Sammensætninger og fremgangsmåder til behandling af osteoartritis | |
DK3272879T3 (da) | Transposonendesammensætninger og fremgangsmåder til modificering af nukleinsyrer | |
DK2247582T3 (da) | Vandfri, krystallinsk form af dimethoxydocetaxel og fremgangsmåder til fremstilling heraf | |
DK3006459T3 (da) | Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion | |
DK3795573T3 (da) | Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf | |
DK3128014T3 (da) | Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger | |
DK2231565T3 (da) | Fremgangsmåder til fremstilling af clorerede carbonhydrider | |
DK2570467T3 (da) | Sammensætninger af tetrafluorpropen og carbonhydrider | |
BRPI0922084A2 (pt) | Composições e métodos compreendendo variantes de serina protease | |
DK3181134T3 (da) | Bifidobakterier til behandling af diabetes og relaterede tilstande | |
DK3133169T3 (da) | Fremgangsmåder til selektion og amplificering af polynukleotider | |
BRPI0910872A2 (pt) | equipamento de ostomia temporária | |
HK1145339A1 (zh) | 用於定向整合的方法和組合物 | |
DK2419732T3 (da) | Prionfrie nanopartikelsammensætninger og fremgangsmåder | |
EP2413825A4 (en) | IMPLANTS FOR SPINAL APOPHYSIS AND ASSOCIATED METHODS | |
BRPI0912046A2 (pt) | composições de hibridização e métodos | |
DK2446246T3 (da) | Indretning og fremgangsmåde til udvælgelse af partikler | |
DK2513193T3 (da) | Forbedrede blends af polyarylenethere og polyarylensulfider | |
BRPI0816494A2 (pt) | Composição vedante melhorada | |
DK2398902T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer | |
DK2361090T3 (da) | Sammensætninger til behandling af centralt medieret kvalme og opkastning |